• Monday, August 17, 2020 @ 12:00 am

2021 is set to be a transformational year for Polyphor when phase III “FORTRESS” trial results of balixafortide in breast cancer report. Venture Valuation forecasts peak sales of CHF 700+ mn with potentially more to come from additional indications and drug combinations. Cash life into mid 2021 is sufficient to reach the first major value inflection point (ORR results).

Key catalysts include

  1. Start inhaled murepavadin phase I trial (Q4 2020)
  2. “FORTRESS” ORR results (H1 2021)
  3. "FORTRESS" PFS results (Q4 2021)

Go to the Polyphor Valuation Report by Valuationlab

You may also be interested in